Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 4
1966 2
1967 4
1971 1
1972 5
1973 5
1974 7
1976 3
1977 3
1978 1
1980 1
1982 1
1983 3
1984 2
1985 2
1986 1
1987 3
1990 4
1992 1
1995 1
1996 3
1997 1
2000 2
2001 2
2002 7
2003 6
2004 5
2005 7
2006 8
2007 10
2008 12
2009 10
2010 7
2011 11
2012 22
2013 22
2014 16
2015 14
2016 19
2017 32
2018 24
2019 32
2020 50
2021 45
2022 41
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

408 results
Results by year
Filters applied: . Clear all
Page 1
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand'Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T; MSBase study group. He A, et al. Among authors: ferraro d. Lancet Neurol. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199096
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. Among authors: ferraro d. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
Oligoclonal bands: clinical utility and interpretation cues.
Carta S, Ferraro D, Ferrari S, Briani C, Mariotto S. Carta S, et al. Among authors: ferraro d. Crit Rev Clin Lab Sci. 2022 Sep;59(6):391-404. doi: 10.1080/10408363.2022.2039591. Epub 2022 Mar 11. Crit Rev Clin Lab Sci. 2022. PMID: 35277112
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
Schiavetti I, Cordioli C, Stromillo ML, Teresa Ferrò M, Laroni A, Cocco E, Cola G, Pasquali L, Rilla MT, Signoriello E, Iodice R, Di Sapio A, Lanzillo R, Caleri F, Annovazzi P, Conte A, Liberatore G, Ruscica F, Docimo R, Bonavita S, Ulivelli M, Cavalla P, Patti F, Ferraro D, Clerico M, Immovilli P, Di Filippo M, Salvetti M, Sormani MP. Schiavetti I, et al. Among authors: ferraro d. Mult Scler. 2022 Nov;28(13):2106-2111. doi: 10.1177/13524585221102918. Epub 2022 Jun 23. Mult Scler. 2022. PMID: 35735030
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Jokubaitis V, van der Walt A, Grand'Maison F, Sola P, Ferraro D, Shaygannejad V, Alroughani R, Hupperts R, Terzi M, Boz C, Lechner-Scott J, Pucci E, Van Pesch V, Granella F, Bergamaschi R, Spitaleri D, Slee M, Vucic S, Ampapa R, McCombe P, Ramo-Tello C, Prevost J, Olascoaga J, Cristiano E, Barnett M, Saladino ML, Sanchez-Menoyo JL, Hodgkinson S, Rozsa C, Hughes S, Moore F, Shaw C, Butler E, Skibina O, Gray O, Kermode A, Csepany T, Singhal B, Shuey N, Piroska I, Taylor B, Simo M, Sirbu CA, Sas A, Butzkueven H; MSBase Study Group. Kalincik T, et al. Among authors: ferraro d. Neurology. 2021 Feb 2;96(5):e783-e797. doi: 10.1212/WNL.0000000000011242. Epub 2020 Dec 28. Neurology. 2021. PMID: 33372028 Free PMC article.
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H. Kalincik T, et al. Among authors: ferraro d. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13. J Neurol Neurosurg Psychiatry. 2019. PMID: 30636699
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M, Brescia Morra V, Sola P, Pesci I, Lus G, De Luca G, Lugaresi A, Cavalla P, Montepietra S, Maniscalco GT, Granella F, Ragonese P, Vianello M, Brambilla L, Totaro R, Toscano S, Malucchi S, Petracca M, Moiola L, Ferraro D, Lepore V, Mosconi P, Ponzio M, Tedeschi G, Comi G, Battaglia MA, Filippi M, Amato MP, Trojano M; Italian MS Register. Iaffaldano P, et al. Among authors: ferraro d. Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2):e1141. doi: 10.1212/NXI.0000000000001141. Print 2022 Mar. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35046084 Free PMC article.
Microglia activation: a role for mitochondrial DNA?
Pinti M, Ferraro D, Nasi M. Pinti M, et al. Among authors: ferraro d. Neural Regen Res. 2021 Dec;16(12):2393-2394. doi: 10.4103/1673-5374.313034. Neural Regen Res. 2021. PMID: 33907013 Free PMC article. Review. No abstract available.
Diagnostics of anti-MAG antibody polyneuropathy.
Franciotta D, Gastaldi M, Benedetti L, Garnero M, Biagioli T, Brogi M, Costa G, Fadda E, Andreetta F, Simoncini O, Giannotta C, Bazzigaluppi E, Fazio R, Bedin R, Ferraro D, Mariotto S, Ferrari S, Galloni E, De Riva V, Zardini E, Cortese A, Nobile-Orazio E. Franciotta D, et al. Among authors: ferraro d. Neurol Sci. 2017 Oct;38(Suppl 2):249-252. doi: 10.1007/s10072-017-3024-4. Neurol Sci. 2017. PMID: 29030772 Review.
Diagnostics of dysimmune peripheral neuropathies.
Franciotta D, Gastaldi M, Benedetti L, Pesce G, Biagioli T, Lolli F, Costa G, Melis C, Andreetta F, Simoncini O, Giannotta C, Bazzigaluppi E, Fazio R, Bedin R, Ferraro D, Mariotto S, Ferrari S, Galloni E, De Riva V, Zardini E, Cortese A, Nobile-Orazio E. Franciotta D, et al. Among authors: ferraro d. Neurol Sci. 2017 Oct;38(Suppl 2):243-247. doi: 10.1007/s10072-017-3025-3. Neurol Sci. 2017. PMID: 29030769 Review.
408 results